Yaoru Huang

Taipei Medical University Hospital | TMUH · Department of Radiation Oncology

(1) Background: Predicting the survival of patients in end-of-life care is crucial, and evaluating their performance status is a key factor in determining their likelihood of survival. However, the current traditional methods for predicting survival are limited due to their subjective nature. Wearable technology that provides continuous patient mon...

Due to the challenges and restrictions posed by COVID-19 pandemic, technology and digital solutions played an important role in the rendering of necessary healthcare services, notably in medical education and clinical care. The aim of this scoping review was to analyze and sum up the most recent developments in Virtual Reality (VR) use for therapeu...

Background—Smartphones and wearable devices have become a part and parcel of the healthcare industry. The use of wearable technology has already proved its potentials in improving healthcare research, clinical work, and patient care. The real time data allow the care providers to monitor the patients’ symptoms remotely, prioritize the patients’ vis...

The use of wearable devices (WDs) in healthcare monitoring and management has attracted increasing attention. A major problem is patients’ adherence and acceptance of WDs given that they are already experiencing a disease burden and treatment side effects. This scoping review explored the use of wrist-worn devices in the cancer population, with a s...

Survival prediction is highly valued in end-of-life care clinical practice, and patient performance status evaluation stands as a predominant component in survival prognostication. While current performance status evaluation tools are limited to their subjective nature, the advent of wearable technology enables continual recordings of patients' act...

For treating hepatocellular carcinoma (HCC), local therapies and surgery, including liver transplant, are the first line treatment options; however, several contraindications limit their clinical use. The improvement of radiotherapy (RT) established RT in treating HCC contraindicated against local therapies, including transarterial chemoembolizatio...

Some studies suggest AI-based CDSS could benefit to patients, physicians and even health system. However, criticism also comes along. Our experience suggests AI-based CDSS has its advantage, yet currently also has certain limitations. With AI assistance or not, well-experienced oncologists are still undoubtedly crucial in making real clinical decis...

Lung, liver, bone and brain are the common metastatic sites of breast cancer; however, metastasis to other organs may occur and could mimic primary cancer, especially when histologic presentation is non-specific. Differential diagnosis from primary and secondary malignancies is crucial due to different treatment strategy. In this report, we present...

The prognosis of patients with metastatic cancers has improved in the past decades due to effective chemotherapy and oligometastatic surgery. For inoperable patients, local ablation therapies, such as stereotactic body radiotherapy (SBRT), can provide effective local tumor control with minimal toxicity. Because of its high precision and accuracy, S...

For liver metastases not indicated for operation nor other local therapy, SBRT offers a feasible option for considerable local tumor control. Although our domestic practice was relatively more conservative and dose of SBRT is less than recommended, this initial single-institute experience might help provide an alternative RT option for liver metast...

Background: Few data are available on the tolerance of reirradiation in patients with hepatocellular carcinoma (HCC). This study determined the clinical parameters contributing to the development of radiation-induced liver disease (RILD). Methods: We included 36 patients with HCC who received 2 courses of radiotherapy (RT) to the liver. Using α/...

In patients with unresectable hepatocellular carcinoma (HCC), radiotherapy is considered for patients with a large tumor burden or tumors with portal vein tumor thrombosis, which is not indicated for operation or transarterial chemoembolization. Sorafenib has proved to be effective as a first-line treatment for locally advanced and metastatic HCC....